{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T21:11:25Z","timestamp":1760735485075,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejca.2021.04.027","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T14:00:16Z","timestamp":1622210416000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Treatment with encorafenib and cetuximab of a non\u2013anti\u2013epidermal growth factor receptor\u2013naive patient for BRAF V600E\u2013mutated metastatic colon cancer"],"prefix":"10.1016","volume":"152","author":[{"given":"Reem","family":"El-khoury","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3666-1997","authenticated-orcid":false,"given":"Emilie","family":"Hafliger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Gallois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samy","family":"Louafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Garinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziz","family":"Zaanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9955-4753","authenticated-orcid":false,"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2021.04.027_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41416-019-0526-2","article-title":"Exploring the best treatment options for BRAF-mutant metastatic colon cancer","volume":"121","author":"Taieb","year":"2019","journal-title":"Br J Canc"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.027_bib2","doi-asserted-by":"crossref","first-page":"djw272","DOI":"10.1093\/jnci\/djw272","article-title":"Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer","volume":"109","author":"Taieb","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.ejca.2021.04.027_bib3","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"issue":"35","key":"10.1016\/j.ejca.2021.04.027_bib4","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.19.01340","article-title":"FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109)","volume":"37","author":"Modest","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2021.04.027_bib5","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/bjc.2015.173","article-title":"Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer","volume":"112","author":"Rowland","year":"2015","journal-title":"Br J Canc"},{"year":"2019","series-title":"National library of medicine (US). Identifier NCT04034459, FOLFOXIRI plus cetuximab vs. FOLFOXIRI plus bevacizumab 1st-line in BRAF-mutated mCRC (AIO-KRK-0116)","key":"10.1016\/j.ejca.2021.04.027_bib6"},{"issue":"17","key":"10.1016\/j.ejca.2021.04.027_bib7","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"issue":"7387","key":"10.1016\/j.ejca.2021.04.027_bib8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.ejca.2021.04.027_bib9","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1158\/1078-0432.CCR-16-3155","article-title":"Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study)","volume":"23","author":"Garlan","year":"2017","journal-title":"Clin Canc Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:30:57Z","timestamp":1760733057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921002732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":9,"alternative-id":["S0959804921002732"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.027","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with encorafenib and cetuximab of a non\u2013anti\u2013epidermal growth factor receptor\u2013naive patient for BRAF V600E\u2013mutated metastatic colon cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}